Polypeptides having immunoglobulin-binding activity

By adding an oligopeptide to the C-terminal side of the immunoglobulin-binding domain of Protein A, the polypeptide enhances immunoglobulin adsorption, improving the efficiency of immunoglobulin separation and purification.

JP7587737B2Active Publication Date: 2024-11-21TOSOH CORP
View PDF 13 Cites 0 Cited by

Patent Information

Application Number
JP2020138899
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Filing Date
2020-08-19
Publication Date
2024-11-21
Estimated Expiration
2040-08-19

AI Technical Summary

Technical Problem

Existing polypeptides used for immunoglobulin adsorption, particularly those derived from Staphylococcus bacteria, do not sufficiently enhance the amount of immunoglobulin adsorption when linked to insoluble carriers, limiting the efficiency of antibody drug production.

Method used

A polypeptide is designed by adding an oligopeptide of 3 to 17 amino acid residues, preferably 9 to 16 amino acid residues, to the C-terminal side of the immunoglobulin-binding domain of Protein A derived from Staphylococcus bacteria, with one or more lysine residues for immobilization on an insoluble carrier.

Benefits of technology

This approach significantly improves the immunoglobulin adsorption capacity, allowing for more efficient separation and purification of immunoglobulins.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007587737000001
    Figure 0007587737000001
  • Figure 0007587737000002
    Figure 0007587737000002
  • Figure 0007587737000003
    Figure 0007587737000003
Patent Text Reader

Abstract

To provide a polypeptide comprising the immunoglobulin binding domain of Protein A (SpA) derived from Staphylococcus bacteria, the polypeptide having an improved amount of immunoglobulin adsorption, and to provide an immunoglobulin adsorbent consisting of an insoluble carrier to which the polypeptide is bound.SOLUTION: Provided is a polypeptide having an oligopeptide consisting of 3 to 17 amino acid residues added to the C-terminal side of the immunoglobulin binding domain of SpA and one or more lysine residues added to the C-terminal side of the oligopeptide.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a polypeptide having an activity of specifically binding to immunoglobulin. More specifically, the present invention relates to said polypeptide having an excellent immunoglobulin adsorption amount. [Background technology]

[0002] Antibody drugs are medicines that use antibodies (immunoglobulins), molecules that play an important role in the body's immune system. Due to the diversity of the variable regions of antibodies, antibody drugs bind to target molecules with high specificity and affinity. For this reason, antibody drugs have few side effects, and in recent years, the range of diseases for which they can be used has been expanding, leading to a rapid expansion of the market.

[0003] The production of antibody drugs involves a culture process and a purification process, during which antibody-producing cells are modified and culture conditions are optimized to improve productivity. In the purification process, affinity chromatography is used for crude purification, followed by intermediate purification, final purification, and virus removal before being formulated.

[0004] In the purification process, an affinity adsorbent consisting of an insoluble carrier bound with a protein (ligand) that specifically recognizes antibody molecules is also used. As the ligand, Staphylococcus-derived Protein A (hereinafter, abbreviated as SpA) and Streptococcus-derived Protein G are often used. Among SpAs, Staphylococcus aureus-derived SpA is known to have five immunoglobulin-binding domains, domains E, D, A, B / Z, and C from the N-terminus side. Among these, an alkaline-stable ligand using the amino acid sequence of domain C (Patent Document 1) and a ligand containing a polypeptide in which some amino acid residues of any of domains B / Z and C are deleted (Patent Document 2) have been disclosed.

[0005] When producing antibody drugs, from the viewpoint of improving productivity, it is necessary to improve the amount of antibody adsorbed per affinity adsorbent. As ligands with improved antibody adsorption, a polypeptide in which immunoglobulin-binding domains are linked in tandem (Non-Patent Document 1) and a polypeptide in which a linker is introduced between the immunoglobulin-binding domain and the immobilization tag (Patent Document 3) have been disclosed. However, for SpA, the effect of the linker in improving the adsorption amount is not sufficient. [Prior art documents] [Patent documents]

[0006] [Patent Document 1] Special Publication No. 2010-504754 [Patent Document 2] JP 2012-254981 A [Patent Document 3] WO2017 / 018437 issue [Non-patent literature]

[0007] [Non-Patent Document 1] Freiherr von Roman M et al., Journal of chromatography A, (1347), 80-86, 2014 Summary of the Invention [Problem to be solved by the invention]

[0008] The object of the present invention is to provide a polypeptide containing an immunoglobulin-binding domain of Protein A derived from Staphylococcus bacteria, the polypeptide having an improved immunoglobulin adsorption amount, and an immunoglobulin adsorbent comprising an insoluble carrier to which the polypeptide is bound. [Means for solving the problem]

[0009] As a result of intensive research to solve the above problems, the present inventors have found that by adding an oligopeptide of an appropriate length to the C-terminal side of the immunoglobulin-binding domain of Protein A derived from Staphylococcus aureus bacteria, the amount of immunoglobulin adsorption is improved compared to the immunoglobulin-binding domain, and have thus completed the present invention.

[0010] That is, the present invention includes the following aspects: [1] A polypeptide comprising an immunoglobulin-binding domain of Protein A derived from a bacterium of the genus Staphylococcus, wherein an oligopeptide consisting of 3 to 17 amino acid residues is added to the C-terminus of the domain, and one or more lysine residues are added to the C-terminus of the oligopeptide.

[0011] [2] The polypeptide according to [1], wherein the oligopeptide added to the C-terminus of the immunoglobulin-binding domain of Protein A derived from Staphylococcus aureus is an oligopeptide consisting of 9 to 16 amino acid residues.

[0012] [3] The polypeptide according to [1] or [2], wherein the immunoglobulin-binding domain of Protein A derived from Staphylococcus aureus is any one of the following (a) to (d): (a) a polypeptide comprising at least the amino acid sequence set forth in SEQ ID NO:1; (b) a polypeptide comprising at least a partial sequence of the amino acid sequence set forth in SEQ ID NO:1 and having immunoglobulin-binding activity; (c) a polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 1 or a partial sequence thereof, provided that the amino acid sequence contains substitutions, deletions and / or additions of one or several amino acid residues at one or several positions, and has immunoglobulin-binding activity; (d) A polypeptide comprising an amino acid sequence having 70% or more identity to the amino acid sequence set forth in SEQ ID NO: 1 or a partial sequence thereof, and having immunoglobulin-binding activity.

[0013] [4] A polynucleotide encoding a polypeptide according to any one of [1] to [3].

[0014] [5] An expression vector comprising the polynucleotide described in [4].

[0015] [6] A genetically modified host comprising the polynucleotide described in [4] or the expression vector described in [5].

[0016] [7] The genetically modified host according to [6], wherein the host is Escherichia coli.

[0017] [8] A method for producing a polypeptide, comprising the steps of culturing a genetically recombinant host described in [6] or [7] to express a polypeptide described in any of [1] to [3], and recovering the expressed polypeptide.

[0018] [9] An immunoglobulin adsorbent comprising an insoluble carrier and a polypeptide according to any one of [1] to [3] immobilized on the insoluble carrier.

[0019]

[10] A method for separating immunoglobulins contained in a solution, the method comprising the steps of: adding a solution containing immunoglobulins to a column packed with the adsorbent described in [9] above, thereby adsorbing the immunoglobulins to the adsorbent; and eluting the immunoglobulins adsorbed to the adsorbent. Effect of the Invention

[0020] The present invention relates to a polypeptide comprising at least an immunoglobulin-binding domain of Protein A derived from a bacterium of the genus Staphylococcus, characterized in that a linker (oligopeptide) consisting of 3 to 17 amino acid residues and one or more lysine residues are added to the C-terminus of the domain.

[0021] According to the present invention, an adsorbent with an improved immunoglobulin (antibody) adsorption capacity can be obtained by immobilizing the immunoglobulin-binding domain on an insoluble carrier via the linker, which means that the immunoglobulin contained in a sample can be obtained more efficiently. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0022] The present invention will be described in detail below.

[0023] The immunoglobulin-binding domain of Protein A (hereinafter, SpA) derived from bacteria of the genus Staphylococcus, which constitutes the polypeptide of the present invention, is (I) a polypeptide comprising the entire amino acid sequence of the domain, (II) As long as it has binding activity to immunoglobulin, it may be a polypeptide containing a partial amino acid sequence of the above-mentioned domain. Furthermore, as long as it has binding activity to immunoglobulin, (III) The polypeptide according to (I) or (II) may be a polypeptide containing one or several substitutions, deletions and / or additions of amino acid residues at one or several positions. (IV) It may be a polypeptide comprising an amino acid sequence having 70% or more homology with the amino acid sequence of the polypeptide described in (I) or (II) above (hereinafter, the polypeptides described in (III) and (IV) are collectively referred to as "variants").

[0024] With regard to (II) above, the domain is composed of three α-helices and the loops connecting them. Of the three helices, the two helices on the N-terminal side are the antibody-binding site, and it is known that the antibody-binding ability is maintained even when the helices and loops other than the antibody-binding site are removed (James S. Huston et al., Biophysical Journal, (62), 87-91, 1992). In other words, it is sufficient that the partial amino acid sequence of the immunoglobulin-binding domain of SpA constituting the polypeptide of the present invention includes at least the amino acid sequence of the antibody-binding site.

[0025] As a specific example, when SpA is Protein A (GenBank No. AAA26676) derived from Staphylococcus aureus, it has immunoglobulin-binding domains designated, from the N-terminus, as Domain E (amino acid residues 37 to 92 of GenBank No. AAA26676), Domain D (amino acid residues 93 to 153 of GenBank No. AAA26676), Domain A (amino acid residues 154 to 211 of GenBank No. AAA26676), Domain B / Z (amino acid residues 212 to 269 of GenBank No. AAA26676), and Domain C (amino acid residues 270 to 327 of GenBank No. AAA26676). In this case, the immunoglobulin-binding domain of SpA constituting the polypeptide of the present invention has an immunoglobulin-binding activity, The polypeptide may be a polypeptide including the entire amino acid sequence of at least one of the five domains described above, or a variant thereof. The polypeptide may be a polypeptide containing a partial amino acid sequence of at least one of the five domains described above, or a variant thereof. That is, as long as it has binding activity to immunoglobulin, it may be a polypeptide containing the full-length or partial amino acid sequence of any one of the five domains described above (e.g., domain C), or a variant thereof. The amino acid sequence may be the full length of adjacent domains (e.g., domains B / Z and C) or a partial amino acid sequence (e.g., amino acid residues from the C-terminus of domain B / Z to the N-terminus of domain C), or a variant thereof. The amino acid sequence may be the full length (e.g., domain A and domain C) or partial amino acid sequences (e.g., a partial amino acid sequence of domain A and a partial amino acid sequence of domain C) of any of the five domains mentioned above, or a variant thereof.

[0026] When the immunoglobulin-binding domain of SpA constituting the polypeptide of the present invention is a modified version of domain C (SEQ ID NO: 1) of Protein A derived from Staphylococcus aureus, the following polypeptides (i) to (iv) can be exemplified as preferred embodiments.

[0027] (i) comprising the amino acid sequence set forth in SEQ ID NO: 1, provided that in said amino acid sequence, the amino acid residue corresponding to the second aspartic acid is substituted with glutamic acid, the amino acid residue corresponding to the 49th lysine is substituted with methionine, the amino acid residue corresponding to the 21st asparagine is substituted with tyrosine, the amino acid residue corresponding to the 58th lysine is substituted with glutamic acid, valine, glycine, aspartic acid, or asparagine, the amino acid residue corresponding to the third asparagine is substituted with isoleucine, threonine, or histidine, the amino acid residue corresponding to the 11th asparagine is substituted with lysine or tyrosine, the amino acid residue corresponding to the 15th glutamic acid is substituted with tyrosine, or the amino acid residue corresponding to the 26th asparagine is substituted with tyrosine, or the amino acid residue corresponding to the 27th asparagine is substituted with tyrosine, or the amino acid residue corresponding to the 28th asparagine is substituted with tyrosine, or the amino acid residue corresponding to the 29th asparagine is substituted with tyrosine, or the amino acid residue corresponding to the 30th asparagine is substituted with isoleucine, threonine, or histidine, a polypeptide having at least one of the following substitutions of amino acid residues: substitution of the amino acid residue corresponding to valine at position 40 in SEQ ID NO:1 with alanine; substitution of the amino acid residue corresponding to lysine at position 7 in SEQ ID NO:1 with valine; substitution of the amino acid residue corresponding to serine at position 39 in SEQ ID NO:1 with cysteine ​​or glycine; substitution of the amino acid residue corresponding to glutamic acid at position 47 in SEQ ID NO:1 with valine; substitution of the amino acid residue corresponding to lysine at position 50 in SEQ ID NO:1 with asparagine; substitution of the amino acid residue corresponding to lysine at position 4 in SEQ ID NO:1 with threonine; and substitution of the amino acid residue corresponding to lysine at position 42 in SEQ ID NO:1 with leucine. (ii) A polypeptide comprising the amino acid sequence set forth in SEQ ID NO:1, provided that in said amino acid sequence, at least one amino acid substitution set forth in (i) above is present and further comprises substitution, deletion, insertion and / or addition of one or several amino acid residues at one or several positions other than the position of said amino acid substitution, and has immunoglobulin-binding activity. (iii) a polypeptide having a homology of 70% or more, preferably 80% or more, more preferably 90% or more, and particularly preferably 95% or more to the entire amino acid sequence having at least one amino acid substitution described in (i) in the amino acid sequence shown in SEQ ID NO: 1, in which at least one amino acid substitution remains, and having immunoglobulin-binding activity. (iv) A polypeptide comprising an amino acid sequence according to any one of (i) to (iii), further comprising at least one of the following substitutions in the amino acid sequence: an alanine substitution for the amino acid residue corresponding to glycine at position 29 of SEQ ID NO: 1; an arginine substitution for the amino acid residue corresponding to lysine at position 4 of SEQ ID NO: 1; a glutamic acid substitution for the amino acid residue corresponding to lysine at position 7 of SEQ ID NO: 1; an aspartic acid substitution for the amino acid residue corresponding to asparagine at position 6 of SEQ ID NO: 1; and an arginine substitution for the amino acid residue corresponding to lysine at position 42 of SEQ ID NO: 1. In this specification, "one or several (several positions)" means, for example, 1 to 30, 1 to 20, 1 to 10, 1 to 9, 1 to 8, 1 to 7, 1 to 6, 1 to 5, 1 to 4, 1 to 3, 1 to 2, or 1, depending on the position of the amino acid residue in the three-dimensional structure of the polypeptide and the type of amino acid residue. An example of an amino acid residue substitution other than the above-mentioned amino acid residue substitution is a conservative substitution in which a substitution occurs between amino acids with similar physical and / or chemical properties. In the case of a conservative substitution, it is generally known to those skilled in the art that the function of a protein is maintained between a substitution and a non-substitution. An example of a conservative substitution is a substitution between glycine and alanine, between serine and proline, or between glutamic acid and alanine (Protein Structure and Function, Medical Science International, 9, 2005). The above-mentioned substitutions, deletions, insertions, and / or additions of amino acid residues also include those resulting from naturally occurring mutations (mutants or variants), for example, due to individual differences or differences in species of the microorganism from which the polypeptide or the gene encoding it is derived.

[0028] In addition, in the present specification, "homology" may mean similarity or identity. "Homology" may particularly mean identity. The homology of amino acid sequences can be determined using an alignment program such as BLAST. For example, the identity of amino acid sequences may mean the identity between amino acid sequences calculated using blastp, and specifically, may mean the identity between amino acid sequences calculated using blastp with default parameters.

[0029] In addition, in this specification, "the Xth amino acid in the amino acid sequence described in SEQ ID NO: 1" means an amino acid that is present at the Xth position counting from the N-terminus of the amino acid sequence described in SEQ ID NO: 1. In a specific amino acid sequence, "an amino acid residue corresponding to the Xth amino acid in the amino acid sequence described in SEQ ID NO: 1" means an amino acid residue in the specific amino acid sequence, which is arranged at the same position as the Xth amino acid in the amino acid sequence shown in SEQ ID NO: 1 in the alignment of the specific amino acid sequence with the amino acid sequence of SEQ ID NO: 1. For example, in the case of an amino acid substitution of Asp2Glu (this notation indicates that the amino acid residue corresponding to the second aspartic acid in SEQ ID NO: 1 is replaced with glutamic acid, the same applies below), "an amino acid residue corresponding to the second aspartic acid in SEQ ID NO: 1" in a specific amino acid sequence means an amino acid residue in the specific amino acid sequence, which is arranged at the same position as the second aspartic acid in the amino acid sequence shown in SEQ ID NO: 1 in the alignment of the specific amino acid sequence with the amino acid sequence of SEQ ID NO: 1. In addition, "an amino acid residue corresponding to the Xth amino acid in the amino acid sequence described in SEQ ID NO: 1" in the amino acid sequence described in SEQ ID NO: 1 means the Xth amino acid itself in the amino acid sequence described in SEQ ID NO: 1. That is, the positions of the above-exemplified amino acid substitutions (i.e., amino acid substitutions at the specific positions and optionally other amino acid substitutions such as Gly29Ala) do not necessarily indicate absolute positions in the immunoglobulin-binding domain of SpA of the present invention, but indicate relative positions based on the amino acid sequence set forth in SEQ ID NO: 1. That is, for example, when the immunoglobulin-binding domain of SpA contains an insertion, deletion, or addition of an amino acid residue on the N-terminal side of the positions of the above-exemplified amino acid substitutions, the absolute positions of the amino acid substitutions may vary accordingly. The positions of the above-exemplified amino acid substitutions in the immunoglobulin-binding domain of SpA can be identified, for example, by alignment of the amino acid sequence of the domain with the amino acid sequence set forth in SEQ ID NO: 1. The alignment can be performed, for example, using an alignment program such as BLAST.The same applies to the positions of the above-exemplified amino acid substitutions in any amino acid sequence, such as a variant sequence of the amino acid sequence set forth in SEQ ID NO: 1. Moreover, the amino acid residues before the above-exemplified amino acid substitutions (i.e., amino acid substitutions at the specific positions and optionally other amino acid substitutions such as Gly29Ala) indicate the types of amino acid residues before substitution in the amino acid sequence set forth in SEQ ID NO: 1, and may or may not be conserved in unmodified amino acid sequences other than the amino acid sequence set forth in SEQ ID NO: 1.

[0030] The polypeptide of the present invention is characterized in that an oligopeptide consisting of 3 to 17 amino acid residues (hereinafter also referred to as oligopeptide A) is added to the C-terminus of the immunoglobulin-binding domain of SpA described above, and one or more lysine residues (hereinafter also referred to as oligopeptide B) are added to the C-terminus of oligopeptide A. Of the oligopeptides added to the C-terminus of the domain, oligopeptide B is a residue used for immobilization to an insoluble carrier described below. There is no particular limitation on the length of oligopeptide B (i.e., lysine residues), but it is preferably 1 to 5 residues, more preferably 2 to 4 residues, and even more preferably 3 residues. Oligopeptide A corresponds to a linker between the domain and oligopeptide B. If the length of the linker (oligopeptide A) is too long compared to the domain, the amount of immunoglobulin adsorbed in the immunoglobulin adsorbent produced by immobilization to an insoluble carrier described below decreases, so the length needs to be optimized. As described above, the length of oligopeptide A may be 3 to 17 amino acid residues, preferably 6 to 16 amino acid residues, more preferably 9 to 16 amino acid residues, and even more preferably 12 to 15 amino acid residues. The amino acid sequence of oligopeptide A is not particularly limited, and may be a sequence that easily forms a rigid structure such as (Pro-Ala)n, a sequence that easily forms a flexible structure such as (Gly-Gly-Ser)n, or a random sequence (for example, the amino acid sequence set forth in SEQ ID NO: 20). It is also desirable that the amino acid sequence of oligopeptide A does not contain a sequence consisting of three or more consecutive prolines.

[0031] The immunoglobulin-binding domain of SpA constituting the polypeptide of the present invention may be in the form of two or more linked together. When two or more are linked together, they may be linked directly (directly) or via a linker (e.g., an oligopeptide consisting of 5 to 25 amino acid residues). The immunoglobulin-binding domain of SpA may further contain, at its N-terminus or C-terminus, another oligopeptide other than polypeptide A, polypeptide B, and the above-mentioned domain-linking linker. The other oligopeptide is not particularly limited as long as it does not impair the immunoglobulin-binding activity.

[0032] The polypeptide of the present invention may be produced directly, or may be produced by adding a separately prepared oligopeptide to the immunoglobulin-binding domain of SpA to which no oligopeptide has been added. When produced by the former method, the polypeptide of the present invention can be produced, for example, by expressing it from a genetically recombinant host containing a polynucleotide encoding the polypeptide of the present invention. Examples of the method for producing the polynucleotide include a method in which a polynucleotide encoding the polypeptide of the present invention is directly synthesized and produced, and a method in which a polynucleotide encoding an oligopeptide and a polynucleotide encoding an immunoglobulin-binding domain of SpA not containing the oligopeptide are separately produced, and then the oligopeptide is linked to the N-terminus and / or C-terminus of the immunoglobulin-binding domain of SpA to produce the polypeptide.

[0033] A polynucleotide encoding a polypeptide of the present invention (hereinafter also simply referred to as "polynucleotide of the present invention") can be obtained, for example, by a DNA amplification method such as chemical synthesis or PCR. The DNA amplification method can be carried out using, as a template, a polynucleotide containing a nucleotide sequence to be amplified, such as a nucleotide sequence encoding the polypeptide of the present invention. Examples of polynucleotides used as templates include genomic DNA of an organism that expresses the polypeptide of the present invention, cDNA of the polypeptide of the present invention, and a vector containing the polynucleotide of the present invention.

[0034] The nucleotide sequence of the polynucleotide of the present invention can be designed, for example, by conversion from the amino acid sequence of the polypeptide of the present invention. When converting an amino acid sequence to a nucleotide sequence, a standard codon table can be used, but it is preferable to convert taking into consideration the frequency of codon usage in the host transformed with the polynucleotide of the present invention. For example, when the host is Escherichia coli, the following codons may be converted to avoid the low frequency of usage (so-called rare codons) of AGA / AGG / CGG / CGA for arginine (Arg), ATA for isoleucine (Ile), CTA for leucine (Leu), GGA for glycine (Gly), and CCC for proline (Pro). Analysis of the frequency of codon usage can also be performed by using a public database (for example, the Codon Usage Database on the website of the Kazusa DNA Research Institute).

[0035] The polynucleotide of the present invention may be obtained by obtaining the entire polynucleotide in one go, or by obtaining a polynucleotide consisting of a partial sequence of the polynucleotide and then linking the obtained polynucleotide. The above explanation of the method for obtaining the polynucleotide of the present invention is not limited to the case where the entire sequence is obtained in one go, but can also be applied mutatis mutandis to the case where a partial sequence is obtained.

[0036] Furthermore, a polynucleotide encoding the polypeptide of the present invention may be linked to a polynucleotide encoding the amino acid sequence of any polypeptide, so as to design the polypeptide to encode a fusion amino acid sequence.

[0037] The polypeptide of the present invention can be produced, for example, by culturing a recombinant host containing a polynucleotide of the present invention (hereinafter, also simply referred to as the "recombinant host of the present invention") and expressing the polypeptide. The recombinant host of the present invention can be obtained, for example, by transforming a host with the polynucleotide of the present invention. The host is not particularly limited as long as it is capable of expressing the polypeptide of the present invention by being transformed with the polynucleotide of the present invention. Examples of hosts include animal cells, insect cells, and microorganisms. Among these, examples of animal cells include COS cells, CHO (Chinese Hamster Ovary) cells, Hela cells, NIH3T3 cells, and HEK293 cells, examples of insect cells include Sf9 cells and BTI-TN-5B1-4 cells, and examples of microorganisms include yeast and bacteria. Further, examples of yeast include yeasts of the genus Saccharomyces such as Saccharomyces cerevisiae, yeasts of the genus Pichia such as Pichia pastoris, and yeasts of the genus Schizosaccharomyces such as Schizosaccharomyces pombe, and examples of bacteria include bacteria of the genus Escherichia such as Escherichia coli. Examples of Escherichia coli include JM109 strain and BL21(DE3) strain. Note that using yeast or Escherichia coli as a host is preferable in terms of productivity, and using Escherichia coli as a host is more preferable.

[0038] In the genetically recombinant host of the present invention, the polynucleotide of the present invention may be retained in an expressible manner. Specifically, the polynucleotide of the present invention may be retained so as to be expressed under the control of a promoter that functions in the host. When the host is Escherichia coli, examples of the promoter that functions in the host include the trp promoter, tac promoter, trc promoter, lac promoter, T7 promoter, recA promoter, and lpp promoter.

[0039] In the recombinant host of the present invention, the polynucleotide of the present invention may be present on a vector that autonomously replicates outside of genomic DNA. That is, the recombinant host of the present invention may be prepared by transforming a host with an expression vector containing the polynucleotide of the present invention (hereinafter, also simply referred to as the "expression vector of the present invention"). The expression vector of the present invention is obtained, for example, by inserting the polynucleotide of the present invention into an appropriate position of the expression vector. The expression vector is not particularly limited as long as it is stable and can be replicated in the host to be transformed. When the host is Escherichia coli, examples of the expression vector include pET plasmid vector, pUC plasmid vector, and pTrc plasmid vector. The expression vector of the present invention may be provided with a selection marker such as an antibiotic resistance gene. The appropriate position means a position that does not destroy the replication function, selection marker, and region related to transmissibility of the expression vector. When the polynucleotide of the present invention is inserted into the expression vector, it is preferable to insert it in a state linked to a functional polynucleotide such as a promoter required for expression.

[0040] In the recombinant host of the present invention, the polynucleotide of the present invention may be introduced into genomic DNA. The polynucleotide of the present invention can be introduced into genomic DNA, for example, by a method of gene introduction by homologous recombination. Examples of gene introduction methods by homologous recombination include a method using linear DNA such as the Red-driven integration method (Datsenko, KA, and Wanner, BL, Proc. Natl. Acad. Sci. USA., 97:6640-6645 (2000)), a method using a vector containing a temperature-sensitive replication origin, a method using a vector without a replication origin that functions in the host, and a transduction method using a phage.

[0041] Transformation of a host using a polynucleotide such as an expression vector of the present invention can be carried out, for example, by a method commonly used by those skilled in the art. For example, when Escherichia coli is selected as a host, transformation may be performed by a competent cell method, a heat shock method, an electroporation method, or the like. After transformation, a host containing the polynucleotide of the present invention can be screened by an appropriate method to obtain a recombinant host of the present invention.

[0042] Information regarding genetic engineering techniques such as expression vectors and promoters that can be used in various microorganisms can be obtained from publicly known literature, such as "Basic Microbiology Lectures 8: Genetic Engineering, Kyoritsu Shuppan, 1987."

[0043] When the recombinant host of the present invention contains the expression vector of the present invention, the expression vector of the present invention can be prepared from the recombinant host of the present invention. For example, the expression vector of the present invention can be prepared from a culture obtained by culturing the recombinant host of the present invention by an alkaline extraction method or using a commercially available extraction kit such as the QIAprep Spin Miniprep kit (manufactured by QIAGEN).

[0044] The polypeptide of the present invention can be expressed by culturing the recombinant host of the present invention. The polypeptide of the present invention can be produced by culturing the recombinant host of the present invention to express the polypeptide of the present invention and recovering the expressed polypeptide. That is, a method for producing the polypeptide of the present invention is provided, which includes a step of expressing the polypeptide of the present invention by culturing the recombinant host of the present invention and a step of recovering the expressed polypeptide. The medium composition and culture conditions may be appropriately set depending on various conditions such as the type of host and the characteristics of the polypeptide of the present invention. The medium composition and culture conditions may be set, for example, under conditions that allow the host to grow and allow the polypeptide of the present invention to be expressed. The medium may be, for example, a medium that appropriately contains a carbon source, a nitrogen source, inorganic salts, and various other organic and inorganic components. Specifically, when the host is Escherichia coli, a preferred example of the medium is LB (Luria-Bertani) medium (tryptone 1% (w / v), yeast extract 0.5% (w / v), 1% (w / v) NaCl) supplemented with necessary nutrient sources. In addition, in order to selectively grow the recombinant host of the present invention depending on whether or not the expression vector of the present invention is introduced, it is preferable to add an antibiotic corresponding to the antibiotic resistance gene contained in the expression vector to the medium and culture it. For example, when the expression vector contains a kanamycin resistance gene, kanamycin may be added to the medium. The same applies when the polynucleotide of the present invention is introduced onto genomic DNA. The medium may also contain one or more reducing agents selected from the group consisting of glutathione, cysteine, cystatin, thioglycolate, and dithiothreitol. The medium may also contain a reagent such as glycine that promotes protein secretion from the transformant into the culture medium. For example, when the host is Escherichia coli, it is preferable to add glycine to the medium at 2% (w / v) or less. For example, when the host is Escherichia coli, the culture temperature is generally 10°C to 40°C, preferably 20°C to 37°C, and more preferably around 25°C. For example, when the host is Escherichia coli, the pH of the medium is pH 6.8 to pH 7.4, preferably around pH 7.0.In addition, when the polypeptide of the present invention is expressed under the control of an inducible promoter, it is preferable to induce the polypeptide of the present invention so that it can be well expressed. For example, an inducer according to the type of promoter can be used for expression induction. An example of the inducer is IPTG (isopropyl-β-D-thiogalactopyranoside). When the host is Escherichia coli, for example, when the turbidity (absorbance at 600 nm) of the culture solution becomes about 0.5 to 1.0, an appropriate amount of IPTG is added, and the culture is continued, whereby the expression of the polypeptide of the present invention can be induced. The concentration of IPTG added is, for example, 0.005 to 1.0 mM, preferably 0.01 to 0.5 mM. Expression induction such as IPTG induction can be performed, for example, under conditions well known in the art.

[0045] The polypeptide of the present invention may be isolated and recovered from the culture by a method suitable for its expression form. In this specification, the term "culture" refers to the whole or a part of the culture obtained by culturing. The part is not particularly limited as long as it contains the polypeptide of the present invention. Examples of the part include the cultured cells of the transformant of the present invention and the medium after culturing (i.e., the culture supernatant). For example, when the polypeptide of the present invention accumulates in the culture supernatant, the cells may be separated by centrifugation, and the polypeptide of the present invention may be recovered from the culture supernatant obtained. When the polypeptide of the present invention accumulates within the cells (including the periplasm), the cells may be recovered by centrifugation, and then the cells may be disrupted by adding an enzyme treatment agent or a surfactant, and the polypeptide of the present invention may be recovered from the disrupted cells. The polypeptide of the present invention may be recovered from the culture supernatant or cell disrupted products described above by a known method used for separating and purifying proteins. Examples of the recovery method include ammonium sulfate fractionation, ion exchange chromatography, hydrophobic chromatography, affinity chromatography, gel filtration chromatography, and isoelectric precipitation.

[0046] The polypeptide of the present invention can be used, for example, for the separation or analysis of immunoglobulins (antibodies). When used for the above purpose, it can be used, for example, in the form of an immunoglobulin adsorbent (hereinafter, also simply referred to as "the immunoglobulin adsorbent of the present invention") comprising an insoluble carrier and the polypeptide of the present invention immobilized on the insoluble carrier. In this specification, "separation of immunoglobulins" is not limited to separation of immunoglobulins from a solution in the presence of impurities, but also includes separation between immunoglobulins based on their structure, properties, activity, etc. The insoluble carrier is not particularly limited as long as it is insoluble in an aqueous solution. Examples of insoluble carriers include carriers made from polysaccharides such as agarose, alginate (alginate salt), carrageenan, chitin, cellulose, dextrin, dextran, and starch; carriers made from synthetic polymers such as polyvinyl alcohol, polymethacrylate, poly(2-hydroxyethyl methacrylate), and polyurethane; and carriers made from ceramics such as silica. Among them, carriers made from polysaccharides or synthetic polymers are preferred as insoluble carriers. Examples of the preferred carriers include polymethacrylate gels with hydroxyl groups introduced therein, such as Toyopearl (manufactured by Tosoh Corporation), agarose gels such as Sepharose (manufactured by GE Healthcare), and cellulose gels such as Cellufine (manufactured by JNC Corporation). The shape of the insoluble carrier is not particularly limited. The insoluble carrier may be in a shape that can be packed in a column, for example. The insoluble carrier may be, for example, granular or non-granular. The insoluble carrier may also be, for example, porous or non-porous.

[0047] The polypeptide of the present invention may be immobilized on an insoluble carrier by, for example, covalent bonding. As a specific example, the polypeptide of the present invention can be immobilized on an insoluble carrier by covalently bonding the polypeptide to an insoluble carrier via an active group possessed by the insoluble carrier. That is, the insoluble carrier may have an active group on its surface or the like. Examples of the active group include an N-hydroxysuccinimide (NHS) activated ester group, an epoxy group, a carboxy group, a maleimide group, a haloacetyl group, a tresyl group, a formyl group, and a haloacetamide. As an insoluble carrier having an active group, for example, a commercially available insoluble carrier having an active group may be used as it is, or an active group may be introduced into the insoluble carrier. Examples of commercially available supports having active groups include TOYOPEARL AF-Epoxy-650M, TOYOPEARL AF-Tresyl-650M (both manufactured by Tosoh Corporation), HiTrap NHS-activated HP Columns, NHS-activated Sepharose 4 Fast Flow, Epoxy-activated Sepharose 6B (all manufactured by GE Healthcare), and SulfoLink Coupling Resin (manufactured by Thermo Fisher Scientific).

[0048] An example of a method for introducing active groups onto the support surface is a method in which one of a compound having two or more active sites is reacted with a hydroxy group, epoxy group, carboxy group, amino group, etc. present on the support surface.

[0049] For example, examples of compounds that introduce epoxy groups into hydroxyl groups or amino groups present on the surface of a carrier include epichlorohydrin, ethanediol diglycidyl ether, butanediol diglycidyl ether, and hexanediol diglycidyl ether.

[0050] Further, for example, examples of compounds that introduce a carboxy group into an epoxy group present on the surface of a carrier include 2-mercaptoacetic acid, 3-mercaptopropionic acid, 4-mercaptobutyric acid, 6-mercaptobutyric acid, glycine, 3-aminopropionic acid, 4-aminobutyric acid, and 6-aminohexanoic acid.

[0051] Further, for example, compounds for introducing maleimide groups into hydroxy groups, epoxy groups, carboxy groups, and amino groups present on the surface of a carrier include N-(ε-maleimidocaproic acid) hydrazide, N-(ε-maleimidopropionic acid) hydrazide, 4-(4-N-maleimidophenyl)acetic acid hydrazide, 2-aminomaleimide, 3-aminomaleimide, 4-aminomaleimide, 6-aminomaleimide, 1-(4-aminophenyl)maleimide, 1-(3-aminophenyl)maleimide, 4-(maleimido)phenyl isocyanate, 2-maleimidoacetic acid, and 3-maleimide. Examples include propionic acid, 4-maleimidobutyric acid, 6-maleimidohexanoic acid, N-(α-maleimidoacetoxy)succinimide ester, (m-maleimidobenzoyl)N-hydroxysuccinimide ester, succinimidyl-4-(maleimidomethyl)cyclohexane-1-carbonyl-(6-aminohexanoic acid), succinimidyl-4-(maleimidomethyl)cyclohexane-1-carboxylic acid, (p-maleimidobenzoyl)N-hydroxysuccinimide ester, and (m-maleimidobenzoyl)N-hydroxysuccinimide ester.

[0052] Further, examples of compounds that introduce haloacetyl groups into hydroxy groups or amino groups present on the surface of a carrier include chloroacetic acid, bromoacetic acid, iodoacetic acid, chloroacetic acid chloride, bromoacetic acid chloride, bromoacetic acid bromide, chloroacetic acid anhydride, bromoacetic acid anhydride, iodoacetic acid anhydride, 2-(iodoacetamido)acetic acid-N-hydroxysuccinimide ester, 3-(bromoacetamido)propionic acid-N-hydroxysuccinimide ester, and 4-(iodoacetyl)aminobenzoic acid-N-hydroxysuccinimide ester.

[0053] In addition, as a method for introducing active groups onto the carrier surface, a method in which an ω-alkenylalkane glycidyl ether is reacted with a hydroxy group or an amino group present on the carrier surface, and then the ω-alkenyl moiety is halogenated with a halogenating agent to activate the group can be exemplified. Examples of the ω-alkenylalkane glycidyl ether include allyl glycidyl ether, 3-butenyl glycidyl ether, and 4-pentenyl glycidyl ether. Examples of the halogenating agent include N-chlorosuccinimide, N-bromosuccinimide, and N-iodosuccinimide.

[0054] In addition, as a method for introducing an active group onto the carrier surface, a method for introducing an active group onto a carboxy group present on the carrier surface using a condensation agent and an additive can be exemplified. Examples of the condensation agent include 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC), dicyclohexylcarbodiamide, and carbonyldiimidazole. Examples of the additive include N-hydroxysuccinimide (NHS), 4-nitrophenol, and 1-hydroxybenztriazole.

[0055] The polypeptide of the present invention can be immobilized on an insoluble carrier in, for example, a buffer solution. Examples of the buffer solution include acetate buffer, phosphate buffer, MES (2-Morpholinoethanesulfonic acid) buffer, HEPES (4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid) buffer, Tris buffer, and borate buffer. The reaction temperature during immobilization can be appropriately set depending on various conditions, such as the reactivity of the active group and the stability of the polypeptide of the present invention. The reaction temperature during immobilization may be, for example, 5°C to 50°C, and is preferably 10°C to 35°C.

[0056] The immunoglobulin adsorbent of the present invention can be used for separating immunoglobulins (antibodies) by, for example, forming a column packed with the adsorbent. For example, immunoglobulins can be separated by adding a solution containing immunoglobulins to a column packed with the immunoglobulin adsorbent of the present invention to adsorb the immunoglobulins to the adsorbent, and then eluting the immunoglobulins adsorbed to the adsorbent. The solution containing immunoglobulins can be added to the column using, for example, a liquid delivery means such as a pump. The solution containing immunoglobulins may be solvent-substituted in advance using an appropriate buffer before being added to the column. In addition, the column may be equilibrated using an appropriate buffer before being added to the column. By equilibrating the column, it is expected that, for example, immunoglobulins can be separated with a higher purity. Examples of buffers used for solvent substitution and equilibration include phosphate buffer, acetate buffer, and MES buffer. Such buffers may further contain, for example, 10 mM to 100 mM of an inorganic salt such as sodium chloride. The buffer used for solvent substitution and the buffer used for equilibration may be the same or may not be the same. In addition, when components other than immunoglobulins, such as impurities, remain in the column after passing a solution containing immunoglobulin through the column, such components may be removed from the column before eluting the immunoglobulin adsorbed to the immunoglobulin adsorbent. Components other than immunoglobulins can be removed from the column, for example, using an appropriate buffer. For the buffer used to remove components other than immunoglobulins, the description of the buffer used for solvent replacement or equilibration can be applied mutatis mutandis. The immunoglobulin adsorbed to the immunoglobulin adsorbent can be eluted, for example, by weakening the interaction between the immunoglobulin and the ligand (polypeptide of the present invention). Examples of means for weakening the interaction between the immunoglobulin and the ligand (polypeptide of the present invention) include lowering the pH with a buffer, adding a counter peptide, increasing the temperature, and changing the salt concentration. Specifically, the immunoglobulin adsorbed to the immunoglobulin adsorbent can be eluted, for example, using an appropriate elution solution. Examples of the elution solution include buffers that are more acidic than the buffer used for solvent replacement or equilibration. Examples of the acidic buffer include citrate buffer, glycine hydrochloride buffer, and acetate buffer.The pH of the elution solution can be set within a range that does not impair the functions of immunoglobulin (such as antigen binding ability).

[0057] By separating immunoglobulins (antibodies) by the above-mentioned method, separated immunoglobulins can be obtained. That is, in one embodiment, the method for separating immunoglobulins may be a method for producing immunoglobulins, specifically, a method for producing separated immunoglobulins. Immunoglobulins are obtained, for example, as eluted fractions containing immunoglobulins. That is, fractions containing eluted immunoglobulins can be separated. Separation of fractions may be performed, for example, by a conventional method. Methods for separating fractions include a method of replacing a collection container at regular intervals or at regular volumes, a method of replacing a collection container according to the shape of a chromatogram of the eluate, and a method of separating fractions using an automatic fraction collector such as an autosampler. Furthermore, immunoglobulins can be collected from fractions containing immunoglobulins. Collection of immunoglobulins from fractions containing immunoglobulins may be performed, for example, by a known method used for separating and purifying proteins. EXAMPLES

[0058] The present invention will be described in more detail below based on examples and comparative examples, but the present invention is not limited to the following examples.

[0059] Comparative Example 1 (1) Construction of an expression vector for a polypeptide having immunoglobulin-binding activity (1-1) A polypeptide was designed (SEQ ID NO: 3) in which six immunoglobulin-binding domains of Protein A (hereinafter, SpA) derived from bacteria of the genus Staphylococcus, consisting of the amino acid sequence set forth in SEQ ID NO: 2, were linked together. The domain is a polypeptide in which amino acid substitutions were introduced at six sites to improve chemical stability in domain C of natural SpA (amino acid residues 270 to 327 of GenBank No. AAA26676, SEQ ID NO: 1), and lysine residues were replaced with other amino acids to prevent immobilization of an insoluble carrier within the domain. Specifically, it is a polypeptide in which the following amino acid substitutions have been introduced into the native SpA domain C consisting of the amino acid sequence set forth in SEQ ID NO: 1: Asn3Ile (this notation indicates that the amino acid residue corresponding to the third asparagine in SEQ ID NO: 1 has been substituted with isoleucine, the same applies below). The three lysine residues on the C-terminus of SEQ ID NO: 3 (from position 349 to position 351 in SEQ ID NO: 3) are an oligopeptide added for immobilization on an insoluble carrier.

[0060] (1-2) A polynucleotide encoding a polypeptide consisting of the amino acid sequence shown in SEQ ID NO: 3 designed in (1-1) was designed (SEQ ID NO: 4). The nucleotide sequence shown in SEQ ID NO: 4 is a sequence in which a specific site in the immunoglobulin-binding domain of SpA was converted to a different codon from the amino acid sequence shown in SEQ ID NO: 3 using Escherichia coli type codons, for ease of cloning.

[0061] (1-3) Primers (oligonucleotides) for synthesizing a polynucleotide consisting of the sequence set forth in SEQ ID NO:4 were designed (SEQ ID NOs:5 to 16). Specifically, primers consisting of the sequences set forth in SEQ ID NOs:5 and 6 were designed and synthesized to prepare a polynucleotide fragment consisting of the sequence from 1 to 174 of SEQ ID NO:4, primers consisting of the sequences set forth in SEQ ID NOs:7 and 8 were designed and synthesized to prepare a polynucleotide fragment consisting of the sequence from 151 to 372 of SEQ ID NO:4, primers consisting of the sequences set forth in SEQ ID NOs:9 and 10 were designed and synthesized to prepare a polynucleotide fragment consisting of the sequence from 349 to 522 of SEQ ID NO:4, primers consisting of the sequences set forth in SEQ ID NOs:11 and 12 were designed and synthesized to prepare a polynucleotide fragment consisting of the sequence from 499 to 720 of SEQ ID NO:4, primers consisting of the sequences set forth in SEQ ID NOs:13 and 14 were designed and synthesized to prepare a polynucleotide fragment consisting of the sequence from 697 to 870 of SEQ ID NO:4, and primers consisting of the sequences set forth in SEQ ID NOs:15 and 16 were designed and synthesized to prepare a polynucleotide fragment consisting of the sequence from 847 to 1053 of SEQ ID NO:4. Among the above-mentioned fragments, the overlapping regions (i.e., from 151 to 174, 349 to 372, 499 to 522, 697 to 720, and 847 to 870 in SEQ ID NO: 4) serve as a linker for ligating multiple polynucleotides during cloning. Furthermore, in order to enable ligation to the plasmid pET28a cleaved with the restriction enzymes NcoI and XhoI, the primer consisting of the sequence shown in SEQ ID NO: 5 has an NcoI restriction enzyme site (the region from 20 to 25 in SEQ ID NO: 5), and the primer consisting of the sequence shown in SEQ ID NO: 16 has an XhoI restriction enzyme site (the region from 20 to 25 in SEQ ID NO: 16).

[0062] (1-4) A polynucleotide consisting of the sequence set forth in SEQ ID NO:19 (a polynucleotide encoding the immunoglobulin-binding domain of SpA consisting of the amino acid sequence set forth in SEQ ID NO:2) was used as template DNA, and any one of the oligonucleotides consisting of the sequences set forth in SEQ ID NOs:5 and 6, the oligonucleotides consisting of the sequences set forth in SEQ ID NOs:7 and 8, the oligonucleotides consisting of the sequences set forth in SEQ ID NOs:9 and 10, the oligonucleotides consisting of the sequences set forth in SEQ ID NOs:11 and 12, the oligonucleotides consisting of the sequences set forth in SEQ ID NOs:13 and 14, and the oligonucleotides consisting of the sequences set forth in SEQ ID NOs:15 and 16 was used as a PCR primer set (forward primer and reverse primer). A reaction solution having the composition shown in Table 1 was prepared for each PCR primer set, and PCR was performed by repeating 30 cycles of the reaction of the reaction solution, in which one cycle was a first step at 98°C for 10 seconds and a second step at 58°C for 30 seconds.

[0063] [Table 1]

[0064] (1-5) After purifying each of the six polynucleotides obtained by PCR in (1-4), a mixed solution containing 0.05 pmol of each purified polynucleotide was prepared. 0.05 pmol of plasmid pET-28a, which had been previously digested with restriction enzymes NcoI and XhoI, was added to the mixed solution, and the six polynucleotides were linked and ligated to the plasmid pET28a by Gibson assembly reaction using NEB Builder HiFi DNA Assembly Master Mix (New England Biolabs). The ligation product was used to transform E. coli BL21(DE3) strain, which was then cultured (37°C, 16 hours) on LB (Luria-Bertani) plate medium containing 50 μg / mL kanamycin.

[0065] (1-6) After preparing a reaction solution having the composition shown in Table 2, colony PCR was performed on the transformants obtained in (1-5). Transformants (genetically modified E. coli) in which amplification of a PCR product of about 1000 to 1200 base pairs was confirmed were selected and cultured in LB medium containing 50 μg / mL kanamycin, and then purified using a QIAprep Spin Miniprep kit (manufactured by QIAGEN) to obtain a vector (named pET-SpA6) capable of expressing a polypeptide consisting of the amino acid sequence described in SEQ ID NO: 3. The oligonucleotides consisting of the sequences described in SEQ ID NO: 17 (5'-TAATACGACTCACTATAGGG-3') and SEQ ID NO: 18 (5'-TATGCTAGTTATTGCTCAG-3') were used as primers for colony PCR.

[0066] [Table 2]

[0067] (1-7) Of the expression vector pET-SpA6 obtained in (1-6), the polynucleotide encoding the polypeptide consisting of the amino acid sequence set forth in SEQ ID NO: 3 and its surrounding region were subjected to cycle sequencing reaction using Big Dye Terminator Cycle Sequencing ready Reaction kit (manufactured by Life Sciences Co., Ltd.) based on the chain terminator method, and the nucleotide sequence was analyzed using a fully automated DNA sequencer ABI Prism 3700 DNA analyzer (manufactured by Life Sciences Co., Ltd.). In this analysis, an oligonucleotide consisting of the sequence set forth in SEQ ID NO: 17 or 18 was used as a sequencing primer. As a result of the sequence analysis, it was confirmed that the polynucleotide consisting of the sequence set forth in SEQ ID NO: 4 was inserted into the expression vector pET-SpA6.

[0068] (2) Preparation of Polypeptides Having Immunoglobulin-Binding Activity (2-1) The recombinant E. coli containing pET-SpA6 prepared in (1) was inoculated into 20 mL of 2xYT liquid medium (tryptone 1.6% (w / v), yeast extract 1% (w / v), 0.5% (w / v) NaCl) containing 50 μg / mL kanamycin, and pre-cultured (30°C, 16 hours).

[0069] (2-2) 100 mL of the pre-cultured culture was inoculated into 1 L of 2xYT liquid medium containing 50 μg / mL kanamycin and cultured at 37°C for 2 to 3 hours. Then, 200 μL of 0.5 M IPTG (Isopropyl-β-D-thiogalactopyranoside) was added and the mixture was further cultured overnight at 20°C with shaking.

[0070] (2-3) After the culture, the culture medium was centrifuged to recover 8 g of cultured cells (wet weight). 2 g of the cultured cells were lysed using BugBuster Protein Extraction Reagent (Merck Millipore), and the supernatant obtained by centrifugation was passed through a filter to clarify it.

[0071] (2-4) The supernatant clarified in (2-3) was added to a column packed with IgG Sepharose 6 Fast Flow (GE Healthcare) previously equilibrated with 0.05 M Tris buffer (pH 7.6) containing 0.15 M NaCl (hereinafter referred to as washing buffer), and the column was washed with a washing buffer in an amount 10 times the amount of the carrier packed in the column. Then, 0.1 M glycine-HCl buffer (pH 3.0) (hereinafter referred to as acidic solution) was passed through the column to recover a fraction corresponding to the polypeptide having immunoglobulin-binding activity.

[0072] (2-5) The absorbance of the collected fraction was measured using a spectrophotometer to quantify the polypeptide contained in the fraction. SDS-PAGE was also performed to confirm that the polypeptide was highly purified.

[0073] (3) Preparation of immunoglobulin adsorbent The fraction containing the purified polypeptide prepared in (3-1)(2) was concentrated to one-tenth of its original volume using Amicon Ultra (Merck Millipore), and then a 10-fold volume of sodium phosphate buffer was added to the concentrated solution, and the solution was again concentrated to one-tenth of its original volume using Amicon Ultra (Merck Millipore), thereby concentrating the polypeptide solution and replacing the buffer.

[0074] (3-2) TOYOPEARL AF-Formyl-650 (Tosoh Corporation), an insoluble carrier having a formyl group as an active group, was replaced with pure water and then dried by suction filtration. The water content of the suction-dried gel after suction filtration was measured with a water content meter (Mettler Toledo Corporation), and 0.5 to 3.0 g of the dried gel was added to a stoppered Erlenmeyer flask.

[0075] (3-3) A buffer solution containing 1.0 M NaCl (borate or phosphate buffer) was added to the stoppered Erlenmeyer flask containing the suction-dried gel to swell the suction-dried gel.

[0076] (3-4) The polypeptide concentrate prepared in (3-1) was added to a stoppered Erlenmeyer flask so that the final concentration was 10 g / L, and the mixture was shaken at room temperature to bind the gel and the polypeptide in the flask by forming a Schiff base. After 15 minutes to 4 hours, a portion of the supernatant in the stoppered Erlenmeyer flask was collected, and the amount of the polypeptide immobilized on the gel was calculated from the proportion of unbound polypeptide.

[0077] (3-5) An appropriate amount of 1 M NaBH4 aqueous solution was added and the mixture was shaken at room temperature for 15 minutes to 2 hours to reduce the remaining Schiff bases and prepare an immunoglobulin adsorbent. The prepared adsorbent was washed with water, then replaced with 20% (v / v) ethanol and stored.

[0078] (4) Evaluation of immunoglobulin adsorbents (4-1) The immunoglobulin adsorbent prepared in (3) was prepared into a 50% (w / v) slurry, and 100 μL of the slurry was added to a mini Biospin column (BIORAD).

[0079] (4-2) After washing the column by passing the acidic solution and washing buffer solution through it, an immunoglobulin solution (Japan Blood Products Organization, 43 mg / mL) diluted with the washing buffer solution was added, and the column was shaken at 25°C and 1000 rpm for 2 hours using a thermostatic shaking incubator (TAITEC) to adsorb the immunoglobulin to the adsorbent.

[0080] (4-3) After washing off unadsorbed immunoglobulins by passing a washing buffer, the immunoglobulins adsorbed to the adsorbent were eluted using an acidic solution. The absorbance (wavelength 280 nm) of the eluate was measured using a spectrophotometer, and the static adsorption amount of the adsorbent was calculated from the amount of immunoglobulins contained in the eluate.

[0081] Example 1 (1) A polypeptide was designed in which six immunoglobulin-binding domains of SpA, each consisting of the amino acid sequence set forth in SEQ ID NO: 2, were linked together, and a polypeptide consisting of the amino acid sequence set forth in SEQ ID NO: 20 was added to the C-terminal side of the C-terminal domain (the sixth domain from the N-terminus) along with three lysine residues for immobilization to an insoluble carrier (SEQ ID NO: 21).

[0082] (2) A polynucleotide encoding the polypeptide consisting of the amino acid sequence set forth in SEQ ID NO: 21 designed in (1) was designed (SEQ ID NO: 22) based on the same concept as in Comparative Example 1 (1-2).

[0083] (3) Primers (oligonucleotides) for synthesizing a polynucleotide consisting of the sequence set forth in SEQ ID NO:22 were designed and synthesized (SEQ ID NOs:5 to 15 and 23 to 25). In addition, in SEQ ID NO:22, the region of the immunoglobulin-binding domain of SpA (region from base 1 to base 1044) is identical to the corresponding region in SEQ ID NO:4. Therefore, the primers designed and synthesized here are identical to the primers designed and synthesized in Comparative Example 1 (1-3), except that primers consisting of the sequences set forth in SEQ ID NOs:15 and 23 were designed to prepare a polynucleotide fragment consisting of the sequence from base 847 to base 1065 of SEQ ID NO:22, and primers consisting of the sequences set forth in SEQ ID NOs:24 and 25 were designed to prepare a polynucleotide fragment consisting of the sequence from base 1042 to base 1074 of SEQ ID NO:22. Among the above-mentioned fragments, the overlapping regions (i.e., from 151 to 174, 349 to 372, 499 to 522, 697 to 720, 847 to 870, and 1042 to 1065 of SEQ ID NO:22) serve as a linker for ligating multiple polynucleotides during cloning. Furthermore, in order to be able to ligate to the plasmid pET28a cleaved with the restriction enzymes NcoI and XhoI, the primer consisting of the sequence shown in SEQ ID NO:5 has an NcoI restriction enzyme site (the region from 20 to 25 of SEQ ID NO:5), and the primer consisting of the nucleotide sequence shown in SEQ ID NO:24 has an XhoI restriction enzyme site (the region from 37 to 42 of SEQ ID NO:24 and the region from 20 to 25 of SEQ ID NO:25).

[0084] (4) PCR was performed in the same manner as in Comparative Example 1 (1-4), except that a polynucleotide consisting of the sequence set forth in SEQ ID NO:19 was used as template DNA, and any one of the following oligonucleotides consisting of the sequences set forth in SEQ ID NO:5 and SEQ ID NO:6, oligonucleotides consisting of the sequences set forth in SEQ ID NO:7 and SEQ ID NO:8, oligonucleotides consisting of the sequences set forth in SEQ ID NO:9 and SEQ ID NO:10, oligonucleotides consisting of the sequences set forth in SEQ ID NO:11 and SEQ ID NO:12, oligonucleotides consisting of the sequences set forth in SEQ ID NO:13 and SEQ ID NO:14, and oligonucleotides consisting of the sequences set forth in SEQ ID NO:15 and SEQ ID NO:23 was used as the PCR primer set (forward primer and reverse primer).

[0085] (5) Each of the six types of polynucleotides obtained by PCR in (4) was purified, and a mixed solution containing the purified polynucleotides (six types) and 0.05 pmol each of the oligonucleotides consisting of the amino acid sequences set forth in SEQ ID NOs: 24 and 25 was prepared. Except for this, the polynucleotides were linked and ligated to the plasmid pET28a in the same manner as in Comparative Example 1 (1-5) to obtain a transformant.

[0086] (6) Colony PCR was performed on the transformant obtained in (5) in a manner similar to that in Comparative Example 1 (1-6) to obtain a vector capable of expressing a polypeptide consisting of the amino acid sequence set forth in SEQ ID NO: 21 (designated pET-SpA6ADIRFNV_K3).

[0087] (7) The nucleotide sequence of the expression vector pET-SpA6ADIRFNV_K3 obtained in (6) was analyzed in the same manner as in Comparative Example 1 (1-7). As a result of the sequence analysis, it was confirmed that a polynucleotide consisting of the sequence set forth in SEQ ID NO: 22 was inserted into the expression vector pET-SpA6ADIRFNV_K3.

[0088] (8) In a manner similar to that of Comparative Example 1(2), a polypeptide was prepared from the recombinant Escherichia coli containing the pET-SpA6ADIRNFV_K3 prepared in (7), and in a manner similar to that of Comparative Example 1(3), an immunoglobulin adsorbent was prepared in which the polypeptide was immobilized on an insoluble carrier, and the adsorption amount of the adsorbent was evaluated in a manner similar to that of Comparative Example 1(4).

[0089] Example 2 (1) A polypeptide was designed in which six immunoglobulin-binding domains of SpA, each consisting of the amino acid sequence set forth in SEQ ID NO:2, were linked together, and a polypeptide consisting of the amino acid sequence set forth in SEQ ID NO:26 and three lysine residues for immobilization on an insoluble carrier were added to the C-terminal side of the C-terminal domain (the sixth domain from the N-terminus) (SEQ ID NO:27).

[0090] (2) A polynucleotide encoding the polypeptide consisting of the amino acid sequence set forth in SEQ ID NO: 27 designed in (1) was designed (SEQ ID NO: 28) based on the same concept as in Comparative Example 1 (1-2).

[0091] (3) Primers (oligonucleotides) for synthesizing a polynucleotide consisting of the sequence set forth in SEQ ID NO:28 were designed and synthesized (SEQ ID NOs:5 to 15 and 29 to 31). In addition, in SEQ ID NO:28, the region of the immunoglobulin-binding domain of SpA (region from base 1 to base 1044) is identical to the corresponding region in SEQ ID NO:4. Therefore, the primers designed and synthesized here are identical to the primers designed and synthesized in Comparative Example 1 (1-3), except that primers consisting of the sequences set forth in SEQ ID NOs:15 and 29 were designed to prepare a polynucleotide fragment consisting of the sequence from base 847 to base 1086 of SEQ ID NO:28, and primers consisting of the sequences set forth in SEQ ID NOs:30 and 31 were designed to prepare a polynucleotide fragment consisting of the sequence from base 1063 to base 1095 of SEQ ID NO:28. Among the above-mentioned fragments, the overlapping regions (i.e., from 151 to 174, 349 to 372, 499 to 522, 697 to 720, 847 to 870, and 1063 to 1086 of SEQ ID NO:28) serve as a linker for ligating multiple polynucleotides during cloning. Furthermore, in order to be able to ligate to the plasmid pET28a cleaved with the restriction enzymes NcoI and XhoI, the primer consisting of the sequence shown in SEQ ID NO:5 has an NcoI restriction enzyme site (the region from 20 to 25 of SEQ ID NO:5), and the primer consisting of the nucleotide sequence shown in SEQ ID NO:31 has an XhoI restriction enzyme site (the region from 37 to 42 of SEQ ID NO:30 and the region from 20 to 25 of SEQ ID NO:31).

[0092] (4) PCR was performed in the same manner as in Comparative Example 1 (1-4), except that a polynucleotide consisting of the sequence set forth in SEQ ID NO:19 was used as template DNA, and any one of the following oligonucleotides consisting of the sequences set forth in SEQ ID NOs:5 and 6, the sequences set forth in SEQ ID NOs:7 and 8, the sequences set forth in SEQ ID NOs:9 and 10, the sequences set forth in SEQ ID NOs:11 and 12, the sequences set forth in SEQ ID NOs:13 and 14, and the sequences set forth in SEQ ID NOs:15 and 29 was used as the PCR primer set (forward primer and reverse primer).

[0093] (5) Each of the six types of polynucleotides obtained by PCR in (4) was purified, and a mixed solution containing the purified polynucleotides (six types) and 0.05 pmol each of the oligonucleotides consisting of the amino acid sequences set forth in SEQ ID NOs: 30 and 31 was prepared. Except for this, the polynucleotides were linked and ligated to the plasmid pET28a in the same manner as in Comparative Example 1 (1-5) to obtain a transformant.

[0094] (6) Colony PCR was performed on the transformant obtained in (1-5) in the same manner as in Comparative Example 1 (1-6) to obtain a vector capable of expressing a polypeptide consisting of the amino acid sequence set forth in SEQ ID NO: 27 (designated pET-SpA6(ADIRFNV)2_K3).

[0095] (7) The nucleotide sequence of the expression vector pET-SpA6(ADIRFNV)2_K3 obtained in (6) was analyzed in the same manner as in Comparative Example 1 (1-7). As a result of the sequence analysis, it was confirmed that a polynucleotide consisting of the sequence set forth in SEQ ID NO: 28 was inserted into the expression vector pET-SpA6(ADIRFNV)2_K3.

[0096] (8) In a manner similar to that of Comparative Example 1(2), a polypeptide was prepared from the recombinant Escherichia coli containing the pET-SpA6(ADIRNFV)2_K3 prepared in (7), and in a manner similar to that of Comparative Example 1(3), an immunoglobulin adsorbent was prepared in which the polypeptide was immobilized on an insoluble carrier, and the adsorption amount of the adsorbent was evaluated in a manner similar to that of Comparative Example 1(4).

[0097] Comparative Example 2 (1) A polypeptide was designed in which six immunoglobulin-binding domains of SpA, each consisting of the amino acid sequence set forth in SEQ ID NO:2, were linked together, and a polypeptide consisting of the amino acid sequence set forth in SEQ ID NO:32 and three lysine residues for immobilization on an insoluble carrier were added to the C-terminal side of the C-terminal domain (the sixth domain from the N-terminus) (SEQ ID NO:33).

[0098] (2) A polynucleotide encoding the polypeptide consisting of the amino acid sequence set forth in SEQ ID NO: 33 designed in (1) was designed (SEQ ID NO: 34) based on the same concept as in Comparative Example 1 (1-2).

[0099] (3) Primers (oligonucleotides) for synthesizing a polynucleotide consisting of the sequence set forth in SEQ ID NO: 34 were designed and synthesized (SEQ ID NOs: 5 to 15 and 35 to 37). In addition, in SEQ ID NO: 34, the region of the immunoglobulin-binding domain of SpA (region from base 1 to base 1044) is identical to the corresponding region in SEQ ID NO: 4. Therefore, the primers designed and synthesized here are identical to the primers designed and synthesized in Comparative Example 1 (1-3), except that primers consisting of the sequences set forth in SEQ ID NOs: 15 and 35 were designed to prepare a polynucleotide fragment consisting of the sequence from base 847 to base 1092 of SEQ ID NO: 34, and primers consisting of the sequences set forth in SEQ ID NOs: 36 and 37 were designed to prepare a polynucleotide fragment consisting of the sequence from base 1069 to base 1116 of SEQ ID NO: 34. Among the above-mentioned fragments, the overlapping regions (i.e., from 151 to 174, 349 to 372, 499 to 522, 697 to 720, 847 to 870, and 1069 to 1092 of SEQ ID NO:27) serve as a linker for ligating multiple polynucleotides during cloning. Furthermore, in order to be able to ligate to the plasmid pET28a cleaved with the restriction enzymes NcoI and XhoI, the primer consisting of the sequence shown in SEQ ID NO:5 has an NcoI restriction enzyme site (the region from 20 to 25 of SEQ ID NO:5), and the primer consisting of the nucleotide sequence shown in SEQ ID NO:37 has an XhoI restriction enzyme site (the region from 52 to 57 of SEQ ID NO:36 and the region from 20 to 25 of SEQ ID NO:37).

[0100] (4) PCR was performed in the same manner as in Comparative Example 1 (1-4), except that a polynucleotide consisting of the sequence set forth in SEQ ID NO:19 was used as template DNA, and any one of the following oligonucleotides consisting of the sequences set forth in SEQ ID NOs:5 and 6, the sequences set forth in SEQ ID NOs:7 and 8, the sequences set forth in SEQ ID NOs:9 and 10, the sequences set forth in SEQ ID NOs:11 and 12, the sequences set forth in SEQ ID NOs:13 and 14, and the sequences set forth in SEQ ID NOs:15 and 35 was used as the PCR primer set (forward primer and reverse primer).

[0101] (5) Each of the six types of polynucleotides obtained by PCR in (4) was purified, and a mixed solution containing the purified polynucleotides (six types) and 0.05 pmol each of the oligonucleotides consisting of the amino acid sequences set forth in SEQ ID NOs: 36 and 37 was prepared. Except for this, the polynucleotides were linked and ligated to the plasmid pET28a in the same manner as in Comparative Example 1 (1-5) to obtain a transformant.

[0102] (6) Colony PCR was performed on the transformant obtained in (1-5) in the same manner as in Comparative Example 1 (1-6) to obtain a vector capable of expressing a polypeptide consisting of the amino acid sequence set forth in SEQ ID NO: 33 (designated pET-SpA6(ADIRFNV)3_K3).

[0103] (7) The nucleotide sequence of the expression vector pET-SpA6(ADIRFNV)3_K3 obtained in (6) was analyzed in the same manner as in Comparative Example 1 (1-7). As a result of the sequence analysis, it was confirmed that a polynucleotide consisting of the sequence set forth in SEQ ID NO: 34 was inserted into the expression vector pET-SpA6(ADIRFNV)3_K3.

[0104] (8) In a manner similar to that of Comparative Example 1(2), a polypeptide was prepared from the recombinant Escherichia coli containing the pET-SpA6(ADIRNFV)3_K3 prepared in (7), and in a manner similar to that of Comparative Example 1(3), an immunoglobulin adsorbent was prepared in which the polypeptide was immobilized on an insoluble carrier, and the adsorption amount of the adsorbent was evaluated in a manner similar to that of Comparative Example 1(4).

[0105] Example 3 (1) A polypeptide was designed in which six immunoglobulin-binding domains of SpA, each consisting of the amino acid sequence set forth in SEQ ID NO:2, were linked together, and a polypeptide consisting of the amino acid sequence set forth in SEQ ID NO:38 and three lysine residues for immobilization on an insoluble carrier were added to the C-terminal side of the C-terminal domain (the sixth domain from the N-terminus) (SEQ ID NO:39).

[0106] (2) A polynucleotide encoding the polypeptide consisting of the amino acid sequence set forth in SEQ ID NO: 39 designed in (1) was designed (SEQ ID NO: 40) based on the same concept as in Comparative Example 1 (1-2).

[0107] (3) Primers (oligonucleotides) for synthesizing a polynucleotide consisting of the sequence set forth in SEQ ID NO: 40 were designed and synthesized (SEQ ID NOs: 5 to 15 and 41 to 43). In SEQ ID NO: 40, the region of the immunoglobulin-binding domain of SpA (region from base 1 to base 1044) is identical to the corresponding region in SEQ ID NO: 4. Therefore, the primers designed and synthesized here are identical to the primers designed and synthesized in Comparative Example 1 (1-3), except that primers consisting of the sequences set forth in SEQ ID NOs: 15 and 41 were designed to prepare a polynucleotide fragment consisting of the sequence from base 847 to base 1086 of SEQ ID NO: 40, and primers consisting of the sequences set forth in SEQ ID NOs: 42 and 43 were designed to prepare a polynucleotide fragment consisting of the sequence from base 1063 to base 1095 of SEQ ID NO: 40. Among the above-mentioned fragments, the overlapping regions (i.e., from 151 to 174, 349 to 372, 499 to 522, 697 to 720, 847 to 870, and 1063 to 1086 in SEQ ID NO: 40) serve as a linker for ligating multiple polynucleotides during cloning. Furthermore, in order to be able to ligate to the plasmid pET28a cleaved with the restriction enzymes NcoI and XhoI, the primer consisting of the sequence shown in SEQ ID NO: 5 has an NcoI restriction enzyme site (the region from 20 to 25 in SEQ ID NO: 5), and the primer consisting of the nucleotide sequence shown in SEQ ID NO: 43 has an XhoI restriction enzyme site (the region from 37 to 42 in SEQ ID NO: 42 and the region from 20 to 25 in SEQ ID NO: 43).

[0108] (4) PCR was performed in the same manner as in Comparative Example 1 (1-4), except that a polynucleotide consisting of the sequence set forth in SEQ ID NO:19 was used as template DNA, and any one of the following oligonucleotides consisting of the sequences set forth in SEQ ID NOs:5 and 6, the sequences set forth in SEQ ID NOs:7 and 8, the sequences set forth in SEQ ID NOs:9 and 10, the sequences set forth in SEQ ID NOs:11 and 12, the sequences set forth in SEQ ID NOs:13 and 14, and the sequences set forth in SEQ ID NOs:15 and 41 was used as the PCR primer set (forward primer and reverse primer).

[0109] (5) Each of the six types of polynucleotides obtained by PCR in (4) was purified, and a mixed solution containing the purified polynucleotides (six types) and 0.05 pmol each of the oligonucleotides consisting of the amino acid sequences set forth in SEQ ID NOs: 42 and 43 was prepared. Except for this, the polynucleotides were linked and ligated to the plasmid pET28a in the same manner as in Comparative Example 1 (1-5) to obtain a transformant.

[0110] (6) Colony PCR was performed on the transformant obtained in (1-5) in a manner similar to that in Comparative Example 1 (1-6) to obtain a vector capable of expressing a polypeptide consisting of the amino acid sequence set forth in SEQ ID NO: 39 (designated pET-SpA6(SGG)4SG_K3).

[0111] (7) The nucleotide sequence of the expression vector pET-SpA6(SGG)4SG_K3 obtained in (6) was analyzed in the same manner as in Comparative Example 1 (1-7). As a result of the sequence analysis, it was confirmed that a polynucleotide consisting of the sequence set forth in SEQ ID NO: 40 was inserted into the expression vector pET-SpA6(SGG)4SG_K3.

[0112] (8) In a manner similar to that of Comparative Example 1(2), a polypeptide was prepared from the recombinant Escherichia coli containing the pET-SpA6(SGG)4SG_K3 prepared in (7), and in a manner similar to that of Comparative Example 1(3), an immunoglobulin adsorbent was prepared in which the polypeptide was immobilized on an insoluble carrier, and the adsorption amount of the adsorbent was evaluated in a manner similar to that of Comparative Example 1(4).

[0113] Example 4 (1) A polypeptide was designed in which six immunoglobulin-binding domains of SpA, each consisting of the amino acid sequence set forth in SEQ ID NO:2, were linked together, and a polypeptide consisting of the amino acid sequence set forth in SEQ ID NO:44 and three lysine residues for immobilization on an insoluble carrier were added to the C-terminal side of the C-terminal domain (the sixth domain from the N-terminus) (SEQ ID NO:45).

[0114] (2) A polynucleotide encoding the polypeptide consisting of the amino acid sequence set forth in SEQ ID NO: 45 designed in (1) was designed (SEQ ID NO: 46) based on the same concept as in Comparative Example 1 (1-2).

[0115] (3) Primers (oligonucleotides) for synthesizing a polynucleotide consisting of the sequence set forth in SEQ ID NO: 46 were designed and synthesized (SEQ ID NOs: 5 to 15 and 47 to 49). In addition, in SEQ ID NO: 46, the region of the immunoglobulin-binding domain of SpA (region from base 1 to base 1044) is identical to the corresponding region in SEQ ID NO: 4. Therefore, the primers designed and synthesized here are identical to the primers designed and synthesized in Comparative Example 1 (1-3), except that primers consisting of the sequences set forth in SEQ ID NOs: 15 and 47 were designed to prepare a polynucleotide fragment consisting of the sequence from base 847 to base 1086 of SEQ ID NO: 46, and primers consisting of the sequences set forth in SEQ ID NOs: 48 and 49 were designed to prepare a polynucleotide fragment consisting of the sequence from base 1063 to base 1095 of SEQ ID NO: 46. Among the above-mentioned fragments, the overlapping regions (i.e., from 151 to 174, 349 to 372, 499 to 522, 697 to 720, 847 to 870, and 1063 to 1086 in SEQ ID NO: 46) serve as a linker for ligating multiple polynucleotides during cloning. Furthermore, in order to be able to ligate to the plasmid pET28a cleaved with the restriction enzymes NcoI and XhoI, the primer consisting of the sequence shown in SEQ ID NO: 5 has an NcoI restriction enzyme site (the region from 20 to 25 in SEQ ID NO: 5), and the primer consisting of the nucleotide sequence shown in SEQ ID NO: 49 has an XhoI restriction enzyme site (the region from 37 to 42 in SEQ ID NO: 48 and the region from 20 to 25 in SEQ ID NO: 49).

[0116] (4) PCR was performed in the same manner as in Comparative Example 1 (1-4), except that a polynucleotide consisting of the sequence set forth in SEQ ID NO:19 was used as template DNA, and any one of the following oligonucleotides consisting of the sequences set forth in SEQ ID NOs:5 and 6, the sequences set forth in SEQ ID NOs:7 and 8, the sequences set forth in SEQ ID NOs:9 and 10, the sequences set forth in SEQ ID NOs:11 and 12, the sequences set forth in SEQ ID NOs:13 and 14, and the sequences set forth in SEQ ID NOs:15 and 47 was used as the PCR primer set (forward primer and reverse primer).

[0117] (5) Each of the six types of polynucleotides obtained by PCR in (4) was purified, and a mixed solution containing the purified polynucleotides (six types) and 0.05 pmol each of the oligonucleotides consisting of the amino acid sequences set forth in SEQ ID NOs: 48 and 49 was prepared. Except for this, the polynucleotides were linked and ligated to the plasmid pET28a in the same manner as in Comparative Example 1 (1-5) to obtain a transformant.

[0118] (6) Colony PCR was performed on the transformant obtained in (1-5) in a manner similar to that in Comparative Example 1 (1-6) to obtain a vector capable of expressing a polypeptide consisting of the amino acid sequence set forth in SEQ ID NO: 45 (designated pET-SpA6(PA)7_K3).

[0119] (7) The nucleotide sequence of the expression vector pET-SpA6(PA)7_K3 obtained in (6) was analyzed in the same manner as in Comparative Example 1 (1-7). As a result of the sequence analysis, it was confirmed that a polynucleotide consisting of the sequence set forth in SEQ ID NO: 46 was inserted into the expression vector pET-SpA6(PA)7_K3.

[0120] (8) In a manner similar to that of Comparative Example 1(2), a polypeptide was prepared from the recombinant Escherichia coli containing the pET-SpA6(PA)7_K3 prepared in (7), and in a manner similar to that of Comparative Example 1(3), an immunoglobulin adsorbent was prepared in which the polypeptide was immobilized on an insoluble carrier, and the adsorption amount of the adsorbent was evaluated in a manner similar to that of Comparative Example 1(4).

[0121] The results of comparing the immunoglobulin adsorption amounts of the immunoglobulin adsorbents prepared in each Comparative Example and Example are summarized in Table 3. The linker lengths and sequences shown in Table 3 are those excluding the oligopeptide (3 lysine residues) for immobilization on an insoluble carrier.

[0122] [Table 3]

[0123] By using, as the polypeptide to be immobilized on an insoluble carrier, a polypeptide in which an oligopeptide consisting of 7 and 14 amino acid residues (oligopeptide A) and an oligopeptide for immobilization on an insoluble carrier (oligopeptide B) were added to the C-terminus of the SpA immunoglobulin-binding domain (Examples 1 and 2), the amount of immunoglobulin adsorption was improved compared to a polypeptide in which oligopeptide B was directly linked to the C-terminus of the SpA immunoglobulin-binding domain (Comparative Example 1). In particular, when a polypeptide in which oligopeptide A and oligopeptide B consisting of 14 amino acid residues were added to the C-terminus of the SpA immunoglobulin-binding domain was used, the amount of immunoglobulin adsorption was further improved.

[0124] Furthermore, even when the amino acid sequence of oligopeptide A was changed from a repeating sequence of (Ala-Asp-Ile-Arg-Phe-Asn-Val) (SEQ ID NO: 20) containing a mixture of hydrophobic / hydrophilic / acidic / basic amino acids (Examples 1 and 2) to a repeating sequence of (Ser-Gly-Gly) that tends to form a flexible structure (Example 3) or a repeating sequence of (Pro-Ala) that tends to form a rigid structure (Example 4), the amount of immunoglobulin adsorption was improved. This shows that the improvement in the amount of immunoglobulin adsorption is not dependent on the amino acid sequence of oligopeptide A.

[0125] On the other hand, when the length of oligopeptide A was 21 amino acid residues (Comparative Example 2), the amount of immunoglobulin adsorbed was lower than that of a polypeptide in which oligopeptide B was directly linked to the C-terminus of the SpA immunoglobulin-binding domain (Comparative Example 1). These results show that to improve the amount of immunoglobulin adsorbed, oligopeptide A consisting of 3 to 17 amino acid residues is necessary, and adding oligopeptide A consisting of 9 to 16 amino acid residues is more preferable. [Industrial Applicability]

[0126] As described above, according to the present invention, an adsorbent with an improved immunoglobulin (antibody) adsorption amount can be obtained by immobilizing the immunoglobulin-binding domain on an insoluble carrier via the linker, which means that the immunoglobulin contained in a sample can be obtained more efficiently.

[0127] Therefore, the present invention is useful for producing immunoglobulins in the fields of antibody drugs and antibody diagnostic agents, removing immunoglobulins from biological components, component analysis, and the like.

Claims

1. A polypeptide comprising an immunoglobulin-binding domain of Protein A derived from a bacterium of the genus Staphylococcus, said domain consisting of a polypeptide in which six amino acid sequences set forth in SEQ ID NO: 2 are directly linked together, an oligopeptide consisting of 9 to 16 amino acid residues is added to the C-terminus of said domain, and one or more lysine residues are added to the C-terminus of said oligopeptide.

2. The polypeptide according to claim 1, wherein the oligopeptide added to the C-terminal side of the immunoglobulin-binding domain of Protein A derived from Staphylococcus aureus is an oligopeptide consisting of the amino acid sequence set forth in SEQ ID NO: 26, 38 or 44.

3. A polynucleotide encoding the polypeptide of claim 1 or 2.

4. An expression vector comprising the polynucleotide of claim 3.

5. A genetically modified host comprising the polynucleotide of claim 3 or the expression vector of claim 4.

6. The genetically recombinant host of claim 5 , wherein the host is Escherichia coli.

7. A method for producing a polypeptide, comprising the steps of: culturing the genetically recombinant host according to claim 5 or 6 to express the polypeptide according to claim 1 or 2; and recovering the expressed polypeptide.

8. An immunoglobulin adsorbent comprising an insoluble carrier and the polypeptide according to claim 1 or 2 immobilized on the insoluble carrier.

9. 9. A method for separating immunoglobulins contained in a solution, comprising the steps of: adding a solution containing immunoglobulins to a column packed with the adsorbent according to claim 8 to adsorb the immunoglobulins to the adsorbent; and eluting the immunoglobulins adsorbed to the adsorbent.

Citation Information

Patent Citations

  • Immunoglobulin affinity ligand

    JP2008214350A

  • Protein not containing lysine and cysteine residues

    JP2008266219A

  • Chromatographic ligands containing domain C from Staphylococcus aureus for antibody isolation

    JP2010504754A

  • Chromatography matrix including novel staphylococcus aureus protein a based ligand

    JP2012254981A

  • Media for affinity chromatography

    JP2013235011A